3^rd International Conference on Biopharmaceutics and Biologic Drugs August 30-31, 2017 Philadelphia, USA
(10 Plenary Forums - 1Event)

Lúzio G B Flauzino has completed his Graduation in Industrial Chemistry from the University of Franca (year 2011). During his graduation, he undertook a scientific initiation phase with the group of Natural Products (GPNUF) developing the project- Molecules of interest: isolation, identifi cation, structural modifi cations and evaluation in several biological tests with FAPESP technical training grant (Proc. FAPESP (Proc. No. 2014 / 08404-6), which develops the project phytochemical studies of Villa elliptica and Vellozia variabilis and evaluation in tests against neglected tropical diseases.

Schistosomiasis is a neglected tropical disease that infects over 200 million people worldwide and it is caused by schistosomes (parasitic trematodes). Its treatment relies only on Praziquantel, a drug which shows toxic side eff ects, lack of eff ectiveness against young worms and it may be less useful in the future due to the drug-resistance of schistosomes. Th us, alternative drugs for the treatment are required. Th e crude ethanolic stem extract from Vellozia variabillis (Velloziaceae) has shown in vitro schistosomicidal activity against adult worms of Schistosoma mansoni. Further, the fl avoliganan hydnocarpin D (Figure 1) was isolated from stem extract by chromatographic fractionation plus preparative HPLC; identifi ed by ¹H- NMR, ¹³C-NMR, mass spectrometry methods and evaluated in vitro against S. mansoni. Adult worms of S. mansoni LE strain was recovered from the mesenteric veins of the infected mice and cultured in 24-well plates at 37°C in RPMI1640 media. Hydnocarpin D was dissolved in 10% DMSO and diluted into the medium to give 12.5, 25, 50, 100 and 200 μM. Adult worms were kept for 72 hours and the viability was monitored every 24 hours. As negative control was used adult worms treated with 10% DMSO. Th e biological assay has shown that Hydnocarpin D caused the death of the S. mansoni adult worms (100% at 200 and 100 μM, and 75% at 50 μM aft er 48 hours; 100% at 25 μM aft er 72 hours) and reduced the motor activity signifi cantly of 100% of the adult worms (25, 50, 100, 200 μM aft er 24 hours and at 12,5μM aft er 72 hours). It was also registered a partial tegument alteration at 50, 100 and 200μM. Hydnocarpin D showed good results and can be a good choice to futures studies for the seeking of alternative drugs to schistosomiasis treatment.

Bhabani Sankar Satapathy has 6 years of experience in drug delivery research. He has worked as a Senior Research Fellow in the Dept. of Pharm. Tech., Jadavpur University, India under DST/Inspire fellowship, Govt. of India. His basic research area includes novel approaches like nanoparticles, nanosclae liposomes for targeted drug delivery in the treatment of various cancers like breast and liver. Currently, his research focuses on the brain targeted nanodrug delivery systems for treatment of brain cancer.

Eff ective management of brain related ailments continues to be the challenging area in neuroscience research. Lipid based nanosize carriers owing to their structural uniqueness possess the ability to cross blood-brain barrier (BBB); the major hurdle for the successful transport of therapeutic agents into brain. Th e present study aimed for the development of a phospholipid based nanosize carrier encapsulating a plant derived therapeutic agent and investigation of its BBB crossing potential in vivo. Th e optimized formulation had a size range between 20-50 nm with smooth surface morphology. The formulation showed a narrow size distribution pattern with nearly 8% drug loading capacity. Cryo-transmission electron microscopy study revealed stable formation without any perforation on the outer surface. A sustained drug release profi le was observed for the experimental formulation up to 24 hours study period. Pharmacokinetic and biodistribution data showed an enhanced residence time of the experimental nanocarrier in brain as compared to the free drug. Gamma scintigraphy studies clearly evidenced an

efficient permeation of the nanocarriers through the BBB, as compared to the free drug. Further investigations are warranted to establish its future use in clinical practice.

Saif S Abbas is pursuing his Master’s degree in Pharmaceutics/Pharmacokinetics at Al-Ahliyya Amman University in Jordan. He has completed his graduation from Faculty of Pharmacy and Medical Sciences in Al-Ahliyya Amman University/Jordan in 2013. He worked as a Senior Pharmacist in retail pharmacies and drug stores in Amman/Jordan.

Ivabradine is a new hyperpolarization-activated cyclic nucleotide-gated channel blocker. It has been approved by the FDA in 2015 in management of stable angina and congestive heart failure. Th e aim of this study was to investigate the possibility of pharmacokinetic interaction of a proposed combination of ivabradine and the β-blocker carvedilol in rats using spectroscopy technique. A simple, rapid and sensitive method for validation and determination of ivabradine and carvedilol in the rat’s plasma was developed using HPLC/MS. The method was successfully developed and validated in terms of linearity, precision and accuracy which were within the values accepted by EMEA and ICH. Ivabradine and carvedilol were given both intravenously and orally each alone and as oral combination to fasted Sprague-Dawley rats. Blood samples were withdrawn on scheduled time intervals up to 36 hours and analyzed for each drug. Both compartmental and non-compartmental kinetic analysis was performed on plasma level-time data and the kinetic parameters were calculated from non-compartmental analysis. Results showed signifi cant increase in bioavailability of both drugs in combination (94% for carvedilol and 58% for ivabradine). Also, Cmax was changed signifi cantly from by 165% for carvedilol and 56% for ivabradine when given in combination. There was also a signifi cant decrease in elimination of both drugs expressed as 48% decrease in clearance and 41% increase in the halflife for carvedilol and 32% decrease in clearance and 37% increase of the half-life of ivabradine when given in combination. These changes suggested an interaction on metabolic function of the liver on both drugs by enzyme inhibition. Also, the rate of absorption of ivabradine was slowed by concomitant administration of carvedilol suggesting an interaction on absorption level. In conclusion, a signifi cant kinetic interaction occurred when ivabradine was given orally with carvedilol which makes

dose adjustment of both drugs of much importance.

Osama M Al-Quteimat has completed his Master’s degree in Clinical Pharmacy from University of Jordan. He is a board-certifi ed Oncology Pharmacist working as Senior Inpatient Pharmacist in Cleveland Clinic Abu Dhabi, a leading healthcare institution providing high-quality tertiary healthcare, education and research in United Arab Emirates. His main interests include pharmaceutical care, oncology pharmacy and patient education. He has published many papers in the field of clinical pharmacy in reputed journals.

Pharmacy is a very dynamic profession and the role of the pharmacist is improving with the expansion of the scope of services and the introduction of new subspecialties over time. Moving from being medication dispensers to outcomeoriented and patient-focused care providers; pharmacists will carry more responsibility and commitment to improve their knowledge and practice. Being updated and evidence-based is a key tool to achieve eff ective pharmaceutical care services. The primary purpose of this article is to highlight the concept of “evidence based pharmaceutical care” as professional practice to improve the quality of pharmaceutical care. Th ere is strong data showing that pharmaceutical care lead to improvement in health outcomes and cost-eff ective therapy. More eff orts, policies and qualifi ed staff are needed to establish the “evidencebased pharmaceutical care” as new daily professional practice. Evidence to support pharmacists in their emerging role as care providers is available to improve the effi cacy and quality of pharmaceutical care. Education and specialized training practicing evidence based approach are vital to prepare pharmacists to provide high quality pharmaceutical care. As care providers, pharmacists are eff ective in providing high quality patient care and being members in multidisciplinary clinical teams is needed to give them the opportunity. Evidence based pharmaceutical care is a natural and logical emerging concept in the modern pharmacy practice to achieve high quality and more eff ective pharmaceutical care but still more eff orts and resources are needed to promote new attitude toward more professional career

Krishna Gajjar is a Pharma Student, having Bachelors and Master degree in Pharmacy and currently pursuing PhD as Research Fellow (in Pharmaceutical Sciences- specialization in Medicinal Chemistry) from Nirma University, Ahmedabad, (Gujarat) India, under the guidance of Prof. Anuradha K. Gajjar.

Free fatty-acid receptor 1, is a G-protein-coupled receptor that binds long chain free fatty acids to enhance glucose-dependent insulin secretion and are therefore viable targets for diabetes and metabolic disorders. In the course of the research work, QSAR study, Pharmacophore generation, Molecular Docking, in-silico ADME studies and synthesis was performed to explore the molecular determinants responsible for the agonist action at GPR40. Th e generation of ligand & structure based pharmacophore using the standard tools within Catalyst from diff erent training sets consisted of Hydrophobic, Hydrogen Bond Acceptor and Aromatic ring features as essential aspects. Th e most representative features were selected and included in

the pharmacophore model which was further validated and utilized as a query tool to search 3D databases. CoMFA, CoMSIA and HQSAR were performed on series of 3-aryl-3-ethoxypropanoic acid derivatives to build 3D-QSAR models. Contour maps provided signifi cant insights which gave hints for the modifi cation required to design new molecules with improved biological activity. Molecular docking studies were carried out on designed molecules using Sybyl-X soft ware. Out of these the best Heteroaryl systems, specifi cally the fi ve membered pyrazole ring system was being explored and some of the virtual structures were synthetically explored, and 3-[3-(4-methoxyphenyl)-4-(phenoxymethyl)-1H-pyrazol-1-yl] acetic acid derivative class of compounds were synthesized taking into the account of sustainability and feasibility of the chemistry, which may act as a starting point for the in-house discovery program.